Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: A randomized, multicentre, open-label study

Pharmacopsychiatry

Volumn 42, Issue 3, 2009, Pages 114-121

  Ryckmans, V ^a   Kahn, J P ^b   Modell, S ^c   Werner, C ^d   McQuade, R D ^e   Kerselaers, W ^c   Lissens, J ^c   Sanchez, R ^e  

^a Cabinet de Consultations   (Belgium)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c BRISTOL MYERS SQUIBB   (United States)

^d Otsuka Pharma GmbH   (Germany)

^e OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Atypical antipsychotics; Discontinuation; Dosing; Effectiveness; Schizophrenia; Switching strategies

Indexed keywords

ARIPIPRAZOLE; BIPERIDEN; PROLACTIN; RISPERIDONE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; AGED; AGGRESSION; AGITATION; ANXIETY; ARTICLE; ASTHENIA; BURNING SENSATION; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYNDROME; EYE IRRITATION; FEMALE; GAIT DISORDER; HALLUCINATION; HEADACHE; HUMAN; INSOMNIA; MALE; NAUSEA; OUTPATIENT; PERIPHERAL EDEMA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOMOTOR RETARDATION; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SEXUALITY; SIDE EFFECT; TREATMENT OUTCOME; BLOOD; COGNITION; COMPARATIVE STUDY; CONTROLLED STUDY; HEALTH STATUS; MIDDLE AGED; MULTICENTER STUDY; PATIENT SATISFACTION;

ADULT; ANTIPSYCHOTIC AGENTS; COGNITION; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; PATIENT SATISFACTION; PIPERAZINES; PROLACTIN; QUALITY OF LIFE; QUINOLONES; RISPERIDONE; SCHIZOPHRENIA; SEXUALITY; TREATMENT OUTCOME;

EID: 68149160856     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0028-1112134     Document Type: Article

References (36)

1. Aguglia E, De Vanna M, Onor ML et al. Insight in persons with schizophrenia: Effects of switching from conventional neuroleptics to atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2002 ; 26 : 1229-1233
2. Alvarez E, Bobes J, Gomez JC et al. Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study. Eur Neuropsychopharmacol 2003 ; 13 : 39-48
3. Barkic J, Filakovic P, Radanovic-Grguric L et al. The influence of risperidone on cognitive functions in schizophrenia. Coll Antropol 2003 ; 27 (Suppl 1) : 111-118
4. Casey DE, Carson WH, Saha AR et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 2003 ; 166 : 391-399
5. Chouinard G, Jones BD, Annable L. Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry 1978 ; 135 : 1409-1410
6. Correll CU. Real-life switching strategies with second-generation antipsychotics. J Clin Psychiatry 2006 ; 67 : 160-161
7. Edlinger M, Baumgartner S, Eltanaihi-Furtmuller N et al. Switching between second-generation antipsychotics: why and how? CNS Drugs 2005 ; 19 : 27-42
8. Fleischhacker WW, Hummer M. Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes. Drugs 1997 ; 53 : 915-929
9. Garcia-Cabeza I, Gomez JC, Sacristan JA et al. Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study). BMC Psychiatry 2001 ; 1 : 7
10. Guy W. Clinical Global Impressions (CGI) In: ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare Publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health ; 1976 ; 218-222
11. Harvey PD, Siu CO, Romano S. Randomized, controlled, double-blind, multicenter comparison of the cognitive Effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacology (Berl) 2004 ; 172 : 324-332 (Pubitemid 38392326)
12. Hogan TP, Awad AG. Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol Med 1992 ; 22 : 347-352
13. Kapur S, Zipursky R, Jones C et al. Relationship between dopamine D(2) occupancy, clinical response, and side Effects: a double-blind PET study of fi rst-episode schizophrenia. Am J Psychiatry 2000 ; 157 : 514-520
14. Kay SR, Fiszbein A, Opler LA. Positive and Negative Syndrome Manual. North Tonawanda, NY:Multi-Health Systems ; 1987
15. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987 ; 13 : 261-276
16. Kinon BJ, Basson BR, Gilmore JA et al. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. J Clin Psychiatry 2000 ; 61 : 833-840
17. Kolotkin RL, Crosby RD, Corey-Lisle PK et al. Performance of a weightrelated measure of Quality of Life in a psychiatric sample. Qual Life Res 2006 ; 15 : 587-596
18. Kolotkin RL, Crosby RD, Kosloski KD et al. Development of a brief measure to assess quality of life in obesity. Obes Res 2001 ; 9 : 102-111
19. Loebel A, Siu C, Romano S. Improvement in prosocial functioning after a switch to ziprasidone treatment. CNS Spectr 2004 ; 9 : 3 57-3644
20. Luchins DJ, Freed WJ, Wyatt RJ. The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs. Am J Psychiatry 1980 ; 137 : 1395-1398
21. Masand PS. A review of pharmacologic strategies for switching to atypical antipsychotics. Prim Care Companion J Clin Psychiatry 2005 ; 7 : 121-129
22. Masand PS, Berry SL. Switching antipsychotic therapies. Ann Pharmacother 2000 ; 34 : 200-207
23. McEvoy JP, Lieberman JA, Stroup TS et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006 ; 163 : 600-610
24. MacGahuey CA, Gelenberg AJ, Laukes CA et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000 ; 26 : 25-40
25. Naber D, Moritz S, Lambert M et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001 ; 50 : 79-88 (Pubitemid 32510889)
26. Peuskens J. Switching approach in the management of schizophrenia patients. Int Clin Psychopharmacol 2000 ; 15 (Suppl 4) : S15 - 19
27. Remington G, Kapur S. Atypical antipsychotics: are some more atypical than others? Psychopharmacology (Berl) 2000 ; 148 : 3-15
28. Sanjuan J, Prieto L, Olivares JM et al. GEOPTE Scale of social cognition for psychosis. Actas Esp Psiquiatr 2003 ; 31 : 120-128
29. Stip E. Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics. J Psychiatry Neurosci 2000 ; 25 : 137-153
30. Stroup TS, Lieberman JA, MacEvoy JP et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006 ; 163 : 611-622
31. Tandon R, Devellis RF, Han J et al. Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder. Psychiatry Res 2005 ; 136 : 211-221
32. Tandon R, Marcus RN, Stock EG et al. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophr Res 2006 ; 84 : 77-89
33. Weiden PJ. Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial. J Clin Psychiatry 2007 ; 68 (Suppl 1) : 12-19
34. Weiden PJ, Aquila R, Dalheim L et al. Switching antipsychotic medications. J Clin Psychiatry 1997 ; 58 (Suppl 10) : 63-72
35. Weiden PJ, Simpson GM, Potkin SG et al. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry 2003 ; 64 : 580-588
36. Wolf J, Janssen F, Lublin H et al. A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA). Curr Med Res Opin 2007 ; 23 : 2313-2323